Gland Pharma Q2 FY27 Results: Revenue Up 23% to ₹18,336 Crore, PAT Soars 58%
Gland Pharma's Q2 FY27 revenue increased by 23% to ₹18,336 crore. PAT surged 58% to ₹2,908 crore, and Adjusted EBITDA grew 50% to ₹5,030 crore. The company launched 4 new molecules in the USA and filed 11 ANDAs, receiving 10 approvals.
The significant increase in revenue and profit, coupled with strategic progress in product launches and regulatory approvals, is expected to have a material positive impact on the company's financial standing and market position.
The company reported strong year-on-year growth in revenue, profit after tax, and EBITDA, along with successful product launches and regulatory filings, indicating a positive financial and operational performance.
Gland Pharma Limited announced its financial results for the second quarter of FY27, reporting a significant 23% year-on-year increase in revenue from operations, which reached ₹18,336 crore. Profit After Tax (PAT) saw a substantial surge of 58%, amounting to ₹2,908 crore. The company's Adjusted EBITDA also grew by 50% to ₹5,030 crore.
The company's performance was driven by growth in both its core business segments. CDMO revenue increased by 31% to ₹8,227 crore, supported by recent product launches and increased volumes. Critical Injectables also showed robust growth of 18%, reaching ₹10,109 crore, fueled by new launches and increased demand from existing customers.
Gland Pharma continued its focus on research and development, with R&D expenses rising to ₹1,077 million, representing 6% of consolidated revenue. The company successfully launched four new molecules in the USA during the quarter, including Sugammadex and Erythromycin. Furthermore, eleven ANDAs were filed and ten were approved in Q2 FY27, contributing to a cumulative total of 399 ANDA filings in the U.S. The company also made progress in its co-development partnerships, with fifteen products in development, anticipated for commercialization starting in FY29. The Ready-to-Use (RTU) bags initiative filed 24 products, with 18 approvals so far, addressing a significant market opportunity in the US.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.